Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 4, 2011, Pages 233-244

  Bachmeier, Corbin J ^a   Beaulieu Abdelahad, David ^a   Ganey, Nowell J ^a   Mullan, Michael J ^a   Levin, Gary M ^b,c  

^a ROSKAMP INSTITUTE   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

blood brain barrier (BBB); breast cancer resistance protein (BCRP); desvenlafaxine; P glycoprotein (P gp); venlafaxine

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DESVENLAFAXINE; GLYCOPROTEIN P; RHODAMINE 123; RIFAMPICIN; VENLAFAXINE;

APICAL MEMBRANE; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FLUORESCENT DYES; HUMANS; INTESTINAL ABSORPTION; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RHODAMINE 123; RIFAMPIN; SEROTONIN UPTAKE INHIBITORS;

EID: 79955067599     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.753     Document Type: Article

References (43)

1. Loscher W, Potschka H,. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98. (Pubitemid 40128029)
2. Dano K,. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973; 323: 466-483.
3. Doyle LA, Yang W, Abruzzo LV, et al,. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670. (Pubitemid 29018757)
4. Gerlach JH, Endicott JA, Juranka PF, et al,. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-489. (Pubitemid 17184171)
5. van Veen HW, Callaghan R, Soceneantu L, Sardini A, Konings WN, Higgins CF,. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 1998; 391: 291-295. (Pubitemid 28099017)
6. Schinkel AH, Jonker JW,. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29. (Pubitemid 36078452)
7. Shugarts S, Benet LZ,. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26: 2039-2054.
8. Uhr M, Grauer MT, Holsboer F,. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840-846. (Pubitemid 37205136)
9. Karlsson L, Schmitt U, Josefsson M, et al,. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 2010; 20: 632-640.
10. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE,. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204. (Pubitemid 36373851)
11. Oganesian A, Shilling AD, Young-Sciame R, et al,. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 2009; 42: 47-63.
12. Greiner B, Eichelbaum M, Fritz P, et al., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
13. Westphal K, Weinbrenner A, Zschiesche M, et al., Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68: 345-355.
14. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH,. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-941. (Pubitemid 47359135)
15. Maeng HJ, Kim MH, Jin HE, et al,. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 2007; 35: 1996-2005.
16. Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A,. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 2007; 22: 49-53. (Pubitemid 46178778)
17. Bachmeier C, Mullan M, Paris D,. Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology 2010; 62: 519-529.
18. Artursson P,. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 1990; 79: 476-482. (Pubitemid 20221389)
19. Schuetz EG, Beck WT, Schuetz JD,. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318. (Pubitemid 26066117)
20. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O,. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-1763. (Pubitemid 44427479)
21. Kessel D, Beck WT, Kukuruga D, Schulz V,. Characterization of multidrug resistance by fluorescent dyes. Cancer Res 1991; 51: 4665-4670.
22. Nare B, Prichard RK, Georges E,. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 1994; 45: 1145-1152. (Pubitemid 24195572)
23. Litman T, Brangi M, Hudson E, et al,. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011-2021. (Pubitemid 30386505)
24. Saradhi M, Kumar N, Reddy RC, Tyagi RK,. Pregnane and xenobiotic receptor (PXR): a promiscuous xenosensor in human health and disease. J Endocrinol Reproduct 2006; 10: 1-12.
25. Geick A, Eichelbaum M, Burk O,. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-14587.
26. Anapolsky A, Teng S, Dixit S, Piquette-Miller M,. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and-metabolizing enzymes in mice. Drug Metab Dispos 2006; 34: 405-409. (Pubitemid 43290899)
27. Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H,. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res 2009; 29: 4071-4076.
28. Collett A, Tanianis-Hughes J, Warhurst G,. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 2004; 68: 783-790. (Pubitemid 38953460)
29. Bauer B, Hartz AM, Fricker G, Miller DS,. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004; 66: 413-419. (Pubitemid 39329239)
30. Andersson U, Grankvist K, Bergenheim AT, Behnam-Motlagh P, Hedman H, Henriksson R,. Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation. Med Oncol 2002; 19: 1-9. (Pubitemid 34587751)
31. Liu Y, Zhang JW, Li W, et al., Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006; 91: 356-364. (Pubitemid 43827288)
32. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)
33. Preskorn S, Patroneva A, Silman H, et al., Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29: 39-43.
34. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH,. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993; 268: 14991-14997. (Pubitemid 23206648)
35. Xia CQ, Liu N, Yang D, Miwa G, Gan LS,. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 2005; 33: 637-643. (Pubitemid 40593877)
36. Charlier C, Pinto E, Ansseau M, Plomteux G,. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000; 15: 453-459.
37. Aszalos A,. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007; 12: 838-843. (Pubitemid 47539962)
38. Xia CQ, Yang JJ, Gan LS,. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005; 1: 595-611.
39. Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW,. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001; 35: 62-71.
40. Gareri P, De Fazio P, Gallelli L, et al., Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother 2008; 42: 434-438. (Pubitemid 351429612)
41. Patroneva A, Connolly SM, Fatato P, et al., An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008; 36: 2484-2491.
42. Nichols AI, Fatato P, Shenouda M, et al,. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009; 49: 219-228.
43. Siarheyeva A, Lopez JJ, Glaubitz C,. Localization of multidrug transporter substrates within model membranes. Biochemistry 2006; 45: 6203-6211. (Pubitemid 43727113)